Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dapatech is a branded generic formulation of dapagliflozin, an oral antidiabetic medication developed and marketed by Cytech Pharma in India. As a sodium-glucose cotransporter 2 (SGLT2) inhibitor, it works by blocking the SGLT2 protein in the proximal renal tubules of the kidney. This action prevents the reabsorption of filtered glucose back into the bloodstream, promoting its excretion through urine. Dapatech is primarily indicated for the treatment of type 2 diabetes mellitus to improve glycemic control. Beyond its glucose-lowering effects, it is also recognized for its role in reducing the risk of cardiovascular complications, such as heart failure, and slowing the progression of chronic kidney disease, which are established class indications for SGLT2 inhibitors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dapatech.